Precision Delivery of Steroids as a Rescue Therapy for Gastrointestinal Graft-versus-Host Disease in Pediatric Stem Cell Transplant Recipients
- PMID: 37445274
- PMCID: PMC10342730
- DOI: 10.3390/jcm12134229
Precision Delivery of Steroids as a Rescue Therapy for Gastrointestinal Graft-versus-Host Disease in Pediatric Stem Cell Transplant Recipients
Abstract
Graft versus host disease (GVHD) is one of the most serious complications following stem cell transplant in children and is a major cause of morbidity and mortality. Corticosteroids remain the mainstay of treatment, and although a majority of children respond to systemic steroids, those refractory to or dependent upon corticosteroids suffer from complications secondary to long-term steroid administration. This problem has prompted consideration of steroid-sparing treatment strategies, although the time to clinical remission can be variable. Intraarterial corticosteroid delivery has been used in adults as a rescue therapy in steroid-resistant patients, but its use in children has been limited. We investigated the feasibility of intraarterial steroid administration into the bowel and/or liver in a cohort of six pediatric patients with acute GVHD. All patients successfully underwent treatment with no serious adverse effects. Five of five (100%) patients with gastrointestinal bleeding due to GVHD had rapid symptom improvement by 48 h, which was durable up to three weeks. Three of four (75%) patients with hepatic GVHD had improved cholestasis following intraarterial steroid administration. Our experience with this small cohort preliminarily demonstrated the feasibility and safety of intraarterial steroid administration in children with acute GVHD. This approach warrants consideration as a rescue therapy in steroid-refractory cases and as a "bridge" therapy for children with severe acute GVHD who are transitioning to steroid-sparing regimens.
Keywords: GVHD; intestinal GVHD; intraarterial; locoregional; stem cell transplant.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Long-Term Follow-Up After the Application of Mesenchymal Stromal Cells in Children and Adolescents with Steroid-Refractory Graft-Versus-Host Disease.Stem Cells Dev. 2021 Mar;30(5):234-246. doi: 10.1089/scd.2020.0191. Epub 2021 Feb 19. Stem Cells Dev. 2021. PMID: 33446053
-
Current status of graft-versus-host disease after intestinal transplantation.Curr Opin Organ Transplant. 2019 Apr;24(2):199-206. doi: 10.1097/MOT.0000000000000624. Curr Opin Organ Transplant. 2019. PMID: 30762668 Review.
-
The Potential of Mesenchymal Stromal Cells as Treatment for Severe Steroid-Refractory Acute Graft-Versus-Host Disease: A Critical Review of the Literature.Transplantation. 2016 Nov;100(11):2309-2314. doi: 10.1097/TP.0000000000001029. Transplantation. 2016. PMID: 26714122 Review.
-
Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.Ann Hematol. 2005 Oct;84(10):681-5. doi: 10.1007/s00277-005-1070-0. Epub 2005 Jul 7. Ann Hematol. 2005. PMID: 16001244
-
Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.Biol Blood Marrow Transplant. 2018 Apr;24(4):734-740. doi: 10.1016/j.bbmt.2017.12.772. Epub 2017 Dec 12. Biol Blood Marrow Transplant. 2018. PMID: 29246821 Free PMC article.
References
-
- Mehta R.S., Saliba R.M., Jan A., Shigle T.L., Wang E., Nieto Y., Ciurea S.O., Oran B., Im J., Olson A., et al. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant. Cell. Ther. 2021;27:272.e271–272.e275. doi: 10.1016/j.jtct.2020.12.011. - DOI - PubMed
LinkOut - more resources
Full Text Sources